Expression and Clinical Significance of CD30 and CD56 in Lymphoblastic Lymphoma: A Retrospective Analysis on Paraffin-Embedded Tissues by Immunohistochemistry

References

• Cortelazzo S, Ponzoni M, Ferreri AJM, Hoelzer D. Lymphoblastic lymphoma. Crit Rev Oncol Hematol. 2011;79(3):330–43. doi:10.1016/j.critrevonc.2010.12.003.
   PubMed Web of Science ®Google Scholar
• Diez-Feijóo R, Rodríguez-Sevilla JJ, Salido M, Colomo L, Salar A. T cell lymphoblastic lymphoma with uncommon CD20 expression. Int J Lab Hematol. 2022;44(2):234–5. doi:10.1111/ijlh.13769.
   PubMed Web of Science ®Google Scholar
• Chen L, Xu B, Long X, Gu J, Lou Y, Wang D, Cao Y, Wang N, Li C, Wang G, et al. CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome. J Immunother Cancer. 2020;8(1):e000364. doi:10.1136/jitc-2019-000364.
   PubMed Web of Science ®Google Scholar
• Wang Y, Nowakowski GS, Wang ML, Ansell SM. Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma. J Hematol Oncol. 2018;11(1):57. doi:10.1186/s13045-018-0601-9.
   PubMedGoogle Scholar
• Scarisbrick JJ. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management. Future Oncol. 2017;13(27):2405–11. doi:10.2217/fon-2017-0263.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Cortes J, Estrov Z, Thomas D, Giles FJ, Huh YO, Pierce S, O’Brien S, Faderl S, Kantarjian HM. CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. Leuk Res. 2002;26(7):643–9. doi:10.1016/s0145-2126(01)00188-6.
   PubMed Web of Science ®Google Scholar
• Fischer L, Gökbuget N, Schwartz S, Burmeister T, Rieder H, Brüggemann M, Hoelzer D, Thiel E. CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic phenotype and resistance to induction therapy but no inferior survival after risk-adapted therapy. Haematologica. 2009;94(2):224–9. doi:10.3324/haematol.13543.
   PubMed Web of Science ®Google Scholar
• Yu L, Lu Y, Yao Y, Liu Y, Wang Y, Lai Q, Zhang R, Li W, Wang R, Fu Y, et al. Promiximab-duocarmycin, a new CD56 antibody-drug conjugates, is highly efficacious in small cell lung cancer xenograft models. Oncotarget. 2018;9(4):5197–207. doi:10.18632/oncotarget.23708.
   PubMedGoogle Scholar
• Jagadeesh D, Horwitz S, Bartlett NL, Kim Y, Jacobsen E, Duvic M, Little M, Trepicchio W, Fenton K, Onsum M, et al. Response to Brentuximab vedotin by CD30 expression in non-Hodgkin lymphoma. Oncologist. 2022;27(10):864–73. doi:10.1093/oncolo/oyac137.
   PubMed Web of Science ®Google Scholar
• Laenkholm A-V, Grabau D, Møller Talman M-L, Balslev E, Bak Jylling AM, Tabor TP, Johansen M, Brügmann A, Lelkaitis G, Di Caterino T, et al. An inter-observer Ki67 reproducibility study applying two different assessment methods: on behalf of the Danish Scientific Committee of Pathology, Danish breast cancer cooperative group (DBCG). Acta Oncol. 2018;57(1):83–9. doi:10.1080/0284186X.2017.1404127.
   PubMed Web of Science ®Google Scholar
• Zheng W, Medeiros LJ, Young KH, Goswami M, Powers L, Kantarjian HH, Thomas DA, Cortes JE, Wang SA. CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis. Leuk Lymphoma. 2014;55(3):624–7. doi:10.3109/10428194.2013.820293.
   PubMed Web of Science ®Google Scholar
• Ahuja A, Tyagi S, Seth T, Pati HP, Gahlot G, Tripathi P, Somasundaram V, Saxena R. Comparison of IHC, cytochemistry, and flow cytometry in AML for myeloperoxidase detection. Indian J Hematol Blood Transfus. 2018;34(2):233–9. doi:10.1007/s12288-017-0849-1.
   PubMed Web of Science ®Google Scholar
• Duault C, Kumar A, Taghi Khani A, Lee SJ, Yang L, Huang M, Hurtz C, Manning B, Ghoda L, McDonald T, et al. Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia. Blood. 2021;138(16):1465–80. doi:10.1182/blood.2020009871.
   PubMed Web of Science ®Google Scholar
• Aref S, Azmy E, El-Bakry K, Ibrahim L, Mabed M. Prognostic impact of CD200 and CD56 expression in adult acute lymphoblastic leukemia patients. Hematology. 2018;23(5):263–70. doi:10.1080/10245332.2017.1404276.
   PubMed Web of Science ®Google Scholar
• Ohtsuka E, Kikuchi H, Nasu M, Takita-Sonoda Y, Fujii H, Yokoyama S. Clinicopathological features of adult T-cell leukemia with CD30 antigen expression. Leuk Lymphoma. 1994;15(3-4):303–10. doi:10.3109/10428199409049728.
   PubMed Web of Science ®Google Scholar
• Inaba T, Shimazaki C, Sumikuma T, Ochiai N, Okano A, Hatsuse M, Ashihara E, Kobayashi Y, Rin K, Murakami S, et al. Clinicopathological features of myeloid/natural killer (NK) cell precursor acute leukemia. Leuk Res. 2001;25(2):109–13. doi:10.1016/s0145-2126(00)00099-0.
   PubMed Web of Science ®Google Scholar
• Kwong YL, Chan AC, Liang R, Chiang AK, Chim CS, Chan TK, Todd D, Ho FC. CD56+ NK lymphomas: clinicopathological features and prognosis. Br J Haematol. 1997;97(4):821–9. doi:10.1046/j.1365-2141.1997.1462962.x.
   PubMed Web of Science ®Google Scholar
• Feng Y, Rao H, Lei Y, Huang Y, Wang F, Zhang Y, Xi S, Wu Q, Shao J. CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China. Chin J Cancer. 2017;36(1):43. doi:10.1186/s40880-017-0212-9.
   PubMedGoogle Scholar
• Kimura S, Oshiro Y, Iwasaki H, Kadowaki M, Ogata M, Daa T, Sakata T, Kawauchi S, Wang Z, Takamatsu Y, et al. Clinicopathological findings, prognosis, and Epstein-Barr virus infection in rheumatoid arthritis patients with other iatrogenic immunodeficiency-associated T- and NK-cell lymphoproliferative disorders. BMC Cancer. 2022;22(1):1342. doi:10.1186/s12885-022-10358-0.
   PubMed Web of Science ®Google Scholar
• Rodrigues-Fernandes CI, Abreu LG, Radhakrishnan R, Perez D. E d C, Amaral-Silva GK, Gondak R. d O, Rahimi S, Brennan PA, Fonseca FP, Vargas PA, et al. Prognostic significance of CD30 expression in diffuse large B-cell lymphoma: a systematic review with meta-analysis. J Oral Pathol Med. 2021;50(6):587–93. doi:10.1111/jop.13208.
   PubMed Web of Science ®Google Scholar
• Ward JP, Berrien-Elliott MM, Gomez F, Luo J, Becker-Hapak M, Cashen AF, Wagner-Johnston ND, Maddocks K, Mosior M, Foster M, et al. Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma. Blood. 2022;139(13):1999–2010. doi:10.1182/blood.2021011894.
   PubMed Web of Science ®Google Scholar
• Sahara N, Takeshita A. Prognostic significance of surface markers expressed in multiple myeloma: CD56 and other antigens. Leuk Lymphoma. 2004;45(1):61–5. doi:10.1080/1042819031000149377.
   PubMed Web of Science ®Google Scholar
• Paiva B, Paino T, Sayagues J-M, Garayoa M, San-Segundo L, Martín M, Mota I, Sanchez M-L, Bárcena P, Aires-Mejia I, et al. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood. 2013;122(22):3591–8. doi:10.1182/blood-2013-06-510453.
   PubMed Web of Science ®Google Scholar